EcoDrugPlus

Farnesyl-Diphosphate Farnesyltransferase 1

Ensembl ID : ENSRFEG00010016943
Gene Symbol: FDFT1
1 Cross references
215 Possible Orthologues:

Farnesyltransferase, Caax Box, Beta

Ensembl ID : ENSRFEG00010001422
Gene Symbol: FNTB
1 Cross references
210 Possible Orthologues:

Fatty Acid Amide Hydrolase

Ensembl ID : ENSRFEG00010001067
Gene Symbol: FAAH
1 Cross references
131 Possible Orthologues:

Fibroblast Activation Protein Alpha

Ensembl ID : ENSRFEG00010004921
Gene Symbol: FAP
1 Cross references
127 Possible Orthologues:

Fibroblast Growth Factor 2

Ensembl ID : ENSRFEG00010009335
Gene Symbol: FGF2
1 Cross references
117 Possible Orthologues:

Fibroblast Growth Factor Receptor 1

Ensembl ID : ENSRFEG00010001714
Gene Symbol: FGFR1
1 Cross references
289 Possible Orthologues:

Fibroblast Growth Factor Receptor 2

Ensembl ID : ENSRFEG00010011408
Gene Symbol: FGFR2
1 Cross references
216 Possible Orthologues:

Fibroblast Growth Factor Receptor 3

Ensembl ID : ENSRFEG00010010819
Gene Symbol: FGFR3
1 Cross references
196 Possible Orthologues:

Fibroblast Growth Factor Receptor 4

Ensembl ID : ENSRFEG00010007580
Gene Symbol: FGFR4
1 Cross references
123 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 1

Ensembl ID : ENSRFEG00010004193
Gene Symbol: FLT1
1 Cross references
198 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 3

Ensembl ID : ENSRFEG00010004003
Gene Symbol: FLT3
1 Cross references
133 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 4

Ensembl ID : ENSRFEG00010021493
Gene Symbol: FLT4
1 Cross references
195 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).